Showing results (111-120 of 149) with videos related to

Sort By:
Pageof 15
Hematological Oncology|February 22, 2021
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitorsRoberto Latagliata, Immacolata Attolico, Malgorzata Monika Trawinska, et al.
Hemasphere|November 16, 2020
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid LeukemiaDiletta Fontana, Daniele Ramazzotti, Andrea Aroldi, et al.
Blood|April 23, 2021
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopeniaFrancesca Palandri, Elena Rossi, Daniela Bartoletti, et al.
Cancer|October 15, 2025
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS studyAnna Sicuranza, Paola Pacelli, Adele Santoni, et al.
Leukemia & Lymphoma|November 6, 2020
Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemiaFabio Efficace, Alessandra Iurlo, Andrea Patriarca, et al.
Annals of Hematology|November 27, 2023
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinibOlga Mulas, Elisabetta Abruzzese, Luigiana Luciano, et al.
Hematological Oncology|February 16, 2021
Impact of comorbidities and body mass index on the outcome of polycythemia vera patientsGiulia Benevolo, Elena M Elli, Daniela Bartoletti, et al.
Hemasphere|September 4, 2023
Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMAFabio Efficace, Wael Al Essa, Uwe Platzbecker, et al.
Journal of Clinical Medicine|November 20, 2020
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after DiscontinuationMatteo Dragani, Giovanna Rege Cambrin, Paola Berchialla, et al.
American Journal of Hematology|August 30, 2023
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO studyGiovanni Paolo Maria Zambrotta, Franck E Nicolini, Sarit Assouline, et al.
Pageof 15